# Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation

> **NCT01729676** · — · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 315 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Degarelix or GnRH agonist

## Key facts

- **NCT ID:** NCT01729676
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 315 (ACTUAL)
- **Last updated:** 2014-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01729676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01729676, "Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01729676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*